首页> 外文期刊>JAMA: the Journal of the American Medical Association >Varicella Vaccine, Cost-effective ness Analyses, and Vaccination Policy
【24h】

Varicella Vaccine, Cost-effective ness Analyses, and Vaccination Policy

机译:水痘疫苗,成本效益分析和疫苗接种政策

获取原文
获取原文并翻译 | 示例
           

摘要

Has varicella vaccination been as cost-effective as anticipated when it was universally recommended for children 10 years ago? The answer is complicated and illuminates an evolving controversy regarding the role of cost-effectiveness analyses in deliberations over national vaccine recommendations.In 1994, Lieu and colleagues estimated the cost-effectiveness of a universal childhood varicella vaccination program. Projecting a national vaccination rate of 97% by the sixth year of the program, they estimated a 94% reduction in varicella incidence, accompanied by an 89% reduction in direct medical costs. Accounting as well for reductions in the quantity of parents' and other adults' lost work time attributable to varicella (ie, the "indirect" benefits of vaccination), Lieu et al projected that a varicella vaccination program would save more than dollar 5 for every dollar 1 spent.
机译:水痘疫苗接种是否像十年前普遍推荐给儿童那样具有预期的成本效益?答案很复杂,阐明了成本效益分析在审议国家疫苗建议中的作用方面不断发展的争议。1994年,Lieu及其同事估计了儿童期普遍性水痘疫苗接种计划的成本效益。他们预计到该计划的第六年全国疫苗接种率将达到97%,他们估计水痘的发病率将降低94%,同时直接医疗费用将降低89%。 Lieu等人还计划减少因水痘引起的父母和其他成年人的工作时间减少(即接种疫苗的“间接”好处),因此,每进行一次水痘疫苗接种计划将节省超过5美元花了1美元。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号